Cardiovascular Institute of the South Clinical Research Corporation Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2009
NCT00832572
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Cardiovascular Institute of the South | Cardiovascular Institute of the South Clinical Research Corporation

Active Ingredients

Drugs in Phase 4 Trials (1)

ranolazine (ranexa) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetic Neuropathies (Phase 4)

Myocardial Ischemia (Phase 4)

Nervous System Diseases (Phase 4)

Neuralgia (Phase 4)

Peripheral Nervous System Diseases (Phase 4)

Polyneuropathies (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 1